Sanochemia Establishes New Focus in Peripheral Nervous System Therapy
Sanochemia Pharmazeutika AG has concluded a licensing agreement with Polymun Scientific Immunobiologische Forschung GmbH. The agreement gives Sanochemia access to an innovative formulation technology which - among other applications - could provide new avenues to the treatment of neuropathic pain.
Sanochemia has already developed an experimental topical gel formulation of galantamine which is intended to treat neuropathic pain. When applied to the painful areas of the skin, this novel gel releases microscopic carrier particles (so-called liposomes) which are intended to penetrate the outer layer of the skin and to release galantamine in immediate proximity to the affected nerve endings.
Patent Protection Achieved Sanochemia has secured exclusive intellectual property rights for this new formulation of galantamine and its applications in the major pharmaceutical markets. A Phase II clinical trial, intended to commence during the first half of 2005, is being designed.
Neuropathy results from damage to the highly sensitive sensory nerve endings that are situated immediately below the skin. Such damage, which is a frequent sequel of poorly controlled diabetes or large herpesvirus sores, can cause pain that is unresponsive even to morphine and other opiates.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
